Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 269589
IPSCIO Record ID: 231940
IPSCIO Record ID: 249613
IPSCIO Record ID: 305318
The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.
Licensor has acquired an exclusive, worldwide license for an eluting transmucosal patch platform (ETP) for non-invasive drug delivery in the cannabis field.
Licensor is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.
The license is for transmucosal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids.
Licensorâ€™s oral patch has been shown in clinical studies to be a safe, accurate and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability.
The OralTabs product contains 21mg of full spectrum CBD in each tab and is available in 5 and 30 pack boxes in a wild mint berry flavor with additional packet sizes, formulations and flavors planned for later on in the year.
With concern growing over vaping and the numerous incidents now being reported, Licenseeâ€™s oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles. Licensee is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.
IPSCIO Record ID: 255048
IPSCIO Record ID: 249612
IPSCIO Record ID: 241951
Licensed Product shall mean Licensorâ€™s patch described below hereto in combination with Cannabidiol (CBD) for medical or recreational cannabis, where latter permitted for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted (other than in the field of oral care) or any other product exploiting the Licensee Cannabis IP for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted.
Description of Patch – A â€œEluting Transmucosal Patch Platform (ETP)â€ for non-invasive drug delivery.
Licensor Patents shall mean those patents and patent applications listed below, as well as patents issuing therefrom, and any substitutions, divisions, continuations, continuations-in-part (but only to the extent that they cover the same invention claimed in the foregoing), reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any such patents or patent applications.
1. WO 2012/104834 A1
New oral dissolving films for insulin administration, for treating diabetes.
filed on December 2011. National Phase at Israel and the USA.
2. WO 2010/135053 A2
Dual and single layer dosage forms.
Issued USA patent on April 28, 2015.
3. PCT/IL 2017/050845
Adhesive Oral dissolved Films in Managing Oral Care.
PCT on 31 July 2017.
IPSCIO Record ID: 236901
IPSCIO Record ID: 265496
IPSCIO Record ID: 359060
In accordance with the terms of the Research Agreement, Israelis Licensee and Israelis Licensor will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Licensor agreed not to work, study or develop any technologies with other entities that compete with our work with Licensor for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the partiesâ€™ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.
The Licensor have been conducting research on the use of cannabis to treat disorders with widespread inflammatory responses, such as RA and COVID-19. Parties hope that by decoding the cannabinoid mechanism of action during inflammatory storms, the Parties can treat inflammation associated with COVID-19 where conventional drugs and other therapies have failed.
Rheumatoid arthritis (RA) is a long-term autoimmune disorder. COVID-19 is a virus infection.